asthma
- Conditions
- Health Condition 1: null- COUGH DYSPNEA WHEEZE
- Registration Number
- CTRI/2018/02/011681
- Lead Sponsor
- Dr Pritali Shetye
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1 Patients of either sex with age between 18 to 60 years.
2 Newly diagnosed and patients with stable Bronchial Asthma (clinical features of Tamaka Å?vÄ?sa) (as per GINA Guideline) for at least 6 weeks prior to study entry.
3 Subjects with intermittent & mild persistent controlled bronchial asthma.
4 FEV1 of < 80% of predicted value.
5 Patients willing to participate and written consent.
1 Patients with Status asthmaticus
2 Patients with evidence of malignancy.
3 Patients with uncontrolled Diabetes Mellitus of HbA1c >7.5%.
4 Patients with unstable cardiovascular disease.
5 Patients suffering from other major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders, etc.)
6 Patients with concurrent serious hepatic disorder or renal disorders.
7 Pulmonary disease other than bronchial asthma.
8 Drug abusers.
9 H/o hypersensitivity to the trial drug or any of its ingredients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method trail group has significant effect on asthmaTimepoint: spirometric analysis will be carried on 0th day and 31st day <br/ ><br>CBC abd AEC will be done on 0th and 31st day <br/ ><br>symptoms assessment will be done on 7th, 14th, 21st and 31st day
- Secondary Outcome Measures
Name Time Method ONETimepoint: NONE